| Mt Evans Hospice, Inc 3081 Bergen Peak Drive, Evergreen, CO, 80439 | |
| (303) 674-6400 |
News Archive
In order to ensure that shareholders have up to date information, Q-Med (STO:QMED) has deemed it appropriate to provide an interim trading update for the third quarter of 2009. However, it should be noted that there remains a high degree of uncertainty given the current economic environment.
Amid rising pressure on the UK's mental health services, compounded by COVID-19, the Good Governance Institute and Connect Health have unveiled an industry-leading briefing to support NHS leaders and commissioners in providing the most efficient and best quality care in the community.
Mayo Clinic today announced Saint Marys and Methodist Hospitals will transition to a single licensed hospital operating under the name Mayo Clinic Hospital - Rochester.
Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.
Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.
› Verified 5 days ago
| Name | Mt Evans Hospice, Inc |
|---|---|
| Location | 3081 Bergen Peak Drive, Evergreen, Colorado |
| Hospice ID | 061509 |
| Category | Part of a Home Health Agency |
| Ownership Type | Voluntary Non-profit - Other |
| Profit Type | NON-PROFIT |
| SSA county code | 290 |
News Archive
In order to ensure that shareholders have up to date information, Q-Med (STO:QMED) has deemed it appropriate to provide an interim trading update for the third quarter of 2009. However, it should be noted that there remains a high degree of uncertainty given the current economic environment.
Amid rising pressure on the UK's mental health services, compounded by COVID-19, the Good Governance Institute and Connect Health have unveiled an industry-leading briefing to support NHS leaders and commissioners in providing the most efficient and best quality care in the community.
Mayo Clinic today announced Saint Marys and Methodist Hospitals will transition to a single licensed hospital operating under the name Mayo Clinic Hospital - Rochester.
Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.
Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.
› Verified 5 days ago
| NPI Number | 1346284965 |
| Organization Name | Mount Evans Hospice, Inc. |
| Address | 3721 Evergreen Parkway Evergreen, Colorado, 80439 |
| Phone Number | (303)674-6400 |
News Archive
In order to ensure that shareholders have up to date information, Q-Med (STO:QMED) has deemed it appropriate to provide an interim trading update for the third quarter of 2009. However, it should be noted that there remains a high degree of uncertainty given the current economic environment.
Amid rising pressure on the UK's mental health services, compounded by COVID-19, the Good Governance Institute and Connect Health have unveiled an industry-leading briefing to support NHS leaders and commissioners in providing the most efficient and best quality care in the community.
Mayo Clinic today announced Saint Marys and Methodist Hospitals will transition to a single licensed hospital operating under the name Mayo Clinic Hospital - Rochester.
Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.
Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.
› Verified 5 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 98.2 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 94.5 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 78.2 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 59.7 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 80.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | 82.2 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
In order to ensure that shareholders have up to date information, Q-Med (STO:QMED) has deemed it appropriate to provide an interim trading update for the third quarter of 2009. However, it should be noted that there remains a high degree of uncertainty given the current economic environment.
Amid rising pressure on the UK's mental health services, compounded by COVID-19, the Good Governance Institute and Connect Health have unveiled an industry-leading briefing to support NHS leaders and commissioners in providing the most efficient and best quality care in the community.
Mayo Clinic today announced Saint Marys and Methodist Hospitals will transition to a single licensed hospital operating under the name Mayo Clinic Hospital - Rochester.
Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.
Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.
› Verified 5 days ago
| Home Health Aides | 1.75 |
| Counselors | 0.1 |
| Medical Social Workers | 0.25 |
| Registered Nurses | 1.75 |
| Other Personnel | 0.25 |
| Total Employees | 4.1 |
|---|
News Archive
In order to ensure that shareholders have up to date information, Q-Med (STO:QMED) has deemed it appropriate to provide an interim trading update for the third quarter of 2009. However, it should be noted that there remains a high degree of uncertainty given the current economic environment.
Amid rising pressure on the UK's mental health services, compounded by COVID-19, the Good Governance Institute and Connect Health have unveiled an industry-leading briefing to support NHS leaders and commissioners in providing the most efficient and best quality care in the community.
Mayo Clinic today announced Saint Marys and Methodist Hospitals will transition to a single licensed hospital operating under the name Mayo Clinic Hospital - Rochester.
Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.
Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.
› Verified 5 days ago
| Mt Evans Hospice, Inc Location: 3081 Bergen Peak Drive, Evergreen, Colorado, 80439 Phone: (303) 674-6400 |